イタリア - イタリア語 - AIFA (Agenzia Italiana del Farmaco)

novartis farma s.p.a. - alcaloidi, esclusi quelli della rauwolfia - alcaloidi, esclusi quelli della rauwolfia

欧州連合 - イタリア語 - EMA (European Medicines Agency)

novartis europharm limited - ruxolitinib (come fosfato) - myeloproliferative disorders; polycythemia vera; graft vs host disease - agenti antineoplastici - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. policitemia vera (pv)jakavi è indicato per il trattamento di pazienti adulti affetti da policitemia vera, che sono resistenti o intolleranti di hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ruxolitinibum - compresse - ruxolitinibum 5 mg ut ruxolitinibi phosphas, lactosum monohydricum 71.45 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, hydroxypropylcellulosum, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, pro compresso corresp. natrium 0.32 mg. - myelofibrose, polycythaemia vera, akute graft-versus-host-krankheit - synthetika

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ruxolitinibum - compresse - ruxolitinibum 15 mg ut ruxolitinibi phosphas, lactosum monohydricum 214.35 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, hydroxypropylcellulosum, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, pro compresso corresp. natrium 0.97 mg. - myelofibrose, polycythaemia vera, akute graft-versus-host-krankheit - synthetika

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ruxolitinibum - compresse - ruxolitinibum 20 mg ut ruxolitinibi phosphas, lactosum monohydricum 285.8 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, hydroxypropylcellulosum, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, pro compresso corresp. natrium 1.29 mg. - myelofibrose, polycythaemia vera, akute graft-versus-host-krankheit - synthetika

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ruxolitinibum - compresse - ruxolitinibum 10 mg ut ruxolitinibi phosphas, lactosum monohydricum 142.9 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, hydroxypropylcellulosum, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, pro compresso corresp. natrium 0.65 mg. - myelofibrose, polycythaemia vera, akute graft-versus-host-krankheit - synthetika

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

ebi-pharm ag - okoubaka aubrevillei e cortice d2 - gocce per uso orale - okoubaka aubrevillei e cortice d2 corrisp. ethanolum 70 % v/v. - gemäss homöopathischem arzneimittelbild bei gastroenteritiden nach lebensmittelvergiftungen - farmaci omeopatici

イタリア - イタリア語 - Ministero della Salute

isk biosciences europe n.v. - flazasulfuron; - granulare idrodispersibile - 25.0 g i valori indicati sono per 100 g di prodotto. - diserbante

イタリア - イタリア語 - Ministero della Salute

compo italia s.r.l. - abamectina (aka avermectin); piretrine; - liquido (senza diluizione) - 0.0015 g; 0.04 g i valori indicati sono per 100 g di prodotto. - insetticida-acaricida

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

ebi-pharm ag - argenti nitras d12, bryonia cretica spag. peka d6, echinacea spag. peka d6, glechoma hederacea spag. peka d6, hydrastis canadensis extract canadensis (ph. eur.hom.) d12, magnesio fluoratum (hab) d12, okoubaka aubrevillei e cortice d4, pulsatilla pratensis spag. peka d6 - gocce per uso orale - argenti nitras d12 75 mg, bryonia cretica spag. peka d6 145 mg echinacea spag. peka d6 165 mg, glechoma hederacea spag. peka d6 155 mg, hydrastis canadensis extract canadensis (ph. eur.hom.) d12 75 mg, magnesio fluoratum (hab) d12 75 mg, okoubaka aubrevillei e cortice d4 165 mg, pulsatilla pratensis spag. peka d6 145 mg annuncio solutionem pro 1 g, corrisp. ethanolum 18 % v/v. - gemäss homöopathischem arzneimittelbild bei schleimhautentzündungen im bereich des magen-darmtraktes - farmaci omeopatici